NCT07132021 Efficacy of Trans-auricular Vagus Nerve Stimulation on Upper Extremity Motor Recovery in Stroke Survivors
| NCT ID | NCT07132021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidade Federal de Pernambuco |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-08-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period.
Eligibility Criteria
Inclusion Criteria: Patients aged between 18 and 75 years, with motor impairment in the upper extremity caused by unilateral ischemic or hemorrhagic stroke with stroke onset within the last five years. Exclusion Criteria: * Patients with any contraindication to taVNS, peripheral upper extremity injuries, use of medication affecting cortical excitability in the past 3 months, use of botulinum toxin in the past 3 months, presence of any other neurological disorder, or significant cognitive deficits.
Contact & Investigator
Kátia Monte-Silva, PhD in Neurosciences
STUDY DIRECTOR
Universidade Federal de Pernambuco
Frequently Asked Questions
Who can join the NCT07132021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07132021 currently recruiting?
Yes, NCT07132021 is actively recruiting participants. Contact the research team at gmelodaniel@gmail.com for enrollment information.
Where is the NCT07132021 trial being conducted?
This trial is being conducted at Recife, Brazil.
Who is sponsoring the NCT07132021 clinical trial?
NCT07132021 is sponsored by Universidade Federal de Pernambuco. The principal investigator is Kátia Monte-Silva, PhD in Neurosciences at Universidade Federal de Pernambuco. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.